
Oncology NEWS International
- Oncology NEWS International Vol 17 No 7
- Volume 17
- Issue 7
ThromboGenics and BioInvent Announce Alliance with Roche
UVEN, Belgium-ThromboGenics NV and BioInvent International AB (Lund, Sweden) have entered into a license agreement with Roche for their jointly developed anticancer agent TB-403, a novel monoclonal antibody that blocks PIGF, one of the growth factors responsible for angiogenesis.
UVEN, Belgium-ThromboGenics NV and BioInvent International AB (Lund, Sweden) have entered into a license agreement with Roche for their jointly developed anticancer agent TB-403, a novel monoclonal antibody that blocks PIGF, one of the growth factors responsible for angiogenesis.
Articles in this issue
about 18 years ago
National Cancer Survivors Dayabout 18 years ago
New Indication for Velcade in Previously Untreated Myelomaabout 18 years ago
Risk Factors for Mantle Cell Lymphoma Identifiedabout 18 years ago
RAS Mutations Enhance Chemotherapy in AMLabout 18 years ago
Antidiabetic Agent Metformin May Boost pCRs in Breast Caabout 18 years ago
Eisai Seeks Full FDA Approval for Ontak for CTCLabout 18 years ago
Symptom Screen Plus CA125 Detects Early Ovarian Caabout 18 years ago
Cisplatin Linked to Cardiac Complications in Testicular Ca Patientsabout 18 years ago
Updated X-ACT Study Results Presentedabout 18 years ago
Gene Signature Identifies Low-Risk Patients in MAGE-A3 Trial






















































